Jireh BioPath is developing first-in-class small-molecule immunomodulators targeting the innate immune sensor ZBP1. Unlike conventional antivirals that directly target viruses, our pipeline is based on a Host-Directed Therapy (HDT) strategy that precisely modulates innate immunity to control excessive inflammation while preserving protective immune function.
Broad-Spectrum Antiviral Therapeutic Based on Host-Directed Therapy
An immunomodulatory therapy designed to selectively control pathological inflammation
A Platform Technology with the Potential to Expand into Infectious and Diverse Inflammatory Diseases